Order a Full Advanced Lipid Panel, Not Just Lp(a) Alone
For comprehensive cardiovascular risk assessment and treatment guidance, you should order a complete lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C) and measure Lp(a) once as an adjunct—not Lp(a) in isolation. Lp(a) provides valuable risk-enhancing information but cannot guide lipid-lowering therapy decisions on its own, whereas the standard panel directly informs treatment targets and monitoring.
Why the Full Panel is Essential
LDL-C Remains the Primary Treatment Target
The 2018 ACC/AHA cholesterol guidelines establish that LDL-C is the primary target for lipid-lowering therapy 1. You need baseline LDL-C to:
- Determine treatment intensity (moderate vs. high-intensity statin)
- Monitor therapeutic response
- Adjust therapy to reach guideline-recommended targets
Lp(a) has no established treatment target—the 2019 ACC/AHA primary prevention guidelines explicitly state "no available RCT evidence supports lipoprotein (a) levels as a target of therapy" 2.
Non-HDL-C and Triglycerides Identify Residual Risk
The complete panel allows calculation of non-HDL-C (total cholesterol minus HDL-C), which captures all atherogenic lipoproteins including remnant particles 1. This is particularly important when:
- Triglycerides are ≥200 mg/dL, where LDL-C calculations become unreliable
- Assessing residual risk in patients already on statins
- Identifying patients who may benefit from apoB measurement 2, 1
Recent consensus emphasizes that non-HDL-C should be reported in all standard lipid panels and helps identify patients with elevated atherogenic particle numbers despite acceptable LDL-C 3.
Lp(a) as a Risk-Enhancing Factor, Not a Standalone Test
Lp(a) should be measured once in specific clinical scenarios 1:
- Family history of premature ASCVD
- Personal history of ASCVD not explained by major risk factors
- Intermediate-risk patients where additional risk stratification would change management
An Lp(a) ≥50 mg/dL (or ≥125 nmol/L) is considered a risk-enhancing factor that may tip the balance toward initiating or intensifying statin therapy 2, 1. However, elevated Lp(a) primarily reinforces the need for aggressive LDL-C lowering, not independent treatment 4.
The Clinical Algorithm
Step 1: Order a standard lipid panel (can be non-fasting in most cases) 1
- Total cholesterol, triglycerides, HDL-C, calculated LDL-C
- Calculate non-HDL-C automatically
Step 2: Add Lp(a) measurement (once) if:
- Family history of premature ASCVD
- Early-onset cardiovascular events
- Unexplained ASCVD despite controlled traditional risk factors
- Intermediate 10-year ASCVD risk (7.5-20%) where additional risk stratification would influence treatment decisions 2, 1
Step 3: Consider apoB if:
- Triglycerides ≥200 mg/dL (where LDL-C calculation is less reliable)
- Metabolic syndrome or diabetes
- Discordance suspected between LDL-C and atherogenic particle burden 1, 5
Common Pitfalls to Avoid
Don't order Lp(a) alone because:
- It provides no actionable treatment target
- You'll still need the standard panel to guide statin therapy
- You'll miss other treatable dyslipidemias (elevated LDL-C, low HDL-C, hypertriglyceridemia)
Don't skip the standard panel thinking "advanced" testing is better—the basic lipid panel remains the foundation of cardiovascular risk assessment and the only way to monitor response to lipid-lowering therapy 1, 4.
Don't repeatedly measure Lp(a)—it's genetically determined and remains relatively stable over time, so one measurement is typically sufficient 1.
Practical Considerations
The standard lipid panel is widely available, inexpensive, and covered by insurance. Adding a one-time Lp(a) measurement in appropriate patients provides additional risk stratification at modest cost 6. Studies show that Lp(a) testing is associated with more aggressive lipid-lowering therapy initiation, suggesting it does influence clinical decision-making 6.
In patients with elevated Lp(a), the therapeutic response is to lower LDL-C even more aggressively (since no oral medications effectively lower Lp(a)) and minimize all other cardiovascular risk factors 4. This requires knowing the baseline LDL-C and monitoring its response to therapy—which brings you back to needing the complete lipid panel.